Login to Your Account



Mast starts phase III extension study for sickle cell disease drug

By Michael Fitzhugh
Staff Writer

Tuesday, May 26, 2015

Mast Therapeutics Inc. has initiated a new open-label extension study to evaluate repeat dosing of its experimental sickle cell disease (SCD) therapy, vepoloxamer (MST-188).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription